Are you Dr. Lubiniecki?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 100 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
333 Cottman Ave
Philadelphia, PA 19111Phone+1 215-728-2500Fax+1 215-728-3639- Is this information wrong?
Summary
- Dr. Gregory Lubiniecki, MD is an oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, New Jersey, and Minnesota. He is affiliated with Fox Chase Cancer Center.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2001 - 2004
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1998 - 2001
Johns Hopkins University School of MedicineClass of 1998
Certifications & Licensure
PA State Medical License 2001 - 2024
NJ State Medical License 2004 - 2009
MN State Medical License 1999 - 2001
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 33 citationsThe LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors.Matthew H. Taylor, Emmett V. Schmidt, Corina E. Dutcus, Elaine M. Pinheiro, Yasuhiro Funahashi, Gregory M. Lubiniecki, Drew W. Rasco> ;Future Oncology. 2021 Feb 1
- 148 citationsLong-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 S...Roy S. Herbst, Edward B. Garon, Dong Wan Kim, Byoung Chul Cho, Jose Luis Perez-Gracia, Ji Youn Han, Catherine Dubos Arvis, Margarita Majem, Martin Forster, Isabelle Mo...> ;Journal of Clinical Oncology. 2020 Feb 20
- 1914 citationsPembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, op...Tony Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M. Kowalski, Byoung Chul Cho, Hande Turna, Gilberto de Castro, Vichien Srimuninnimit, Konstantin Laktionov, Igor Bondarenko...> ;Lancet. 2019 May 4
- Join now to see all
Press Mentions
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (Pembrolizumab) plus LENVIMA® (Lenvatinib) in Certain Patients with Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)April 7th, 2023- Merck and Eisai Present Results from Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (Pembrolizumab) plus LENVIMA® (Lenvatinib) Versus LENVIMA Monotherapy in Patients with Unresectable Hepatocellular CarcinomaSeptember 10th, 2022
- Keytruda Fluffs Its Lines in Prostate, Liver Cancer TrialsAugust 4th, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Fox Chase Cancer CenterPhiladelphia, Pennsylvania
